Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › SOUL

SOUL

Semaglutide · T2D + CVD/CKD

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Semaglutide
Population
T2D + CVD/CKD
Official title
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
Sponsor
Novo Nordisk A/S
Phase
Phase 3
Registry status
completed · 2019-06 → 2024-08
Participants
9651
Registry
NCT03914326

Cardiovascular and kidney outcomes

SOUL oral semaglutide 14 mg vs placebo · T2D + CVD/CKD · n = 9650 · 2025 verified

EndpointHR95 % CIEvents, drug vs controlStatus
3-point MACE primary
Three-point MACE: CV death, nonfatal MI, or nonfatal stroke (time to first event)
0.860.77–0.96579 vs 668verified
Cardiovascular death
Death from cardiovascular causes
0.930.80–1.09301 vs 320verified
All-cause death
Death from any cause
0.910.80–1.02528 vs 577verified
Myocardial infarction
Fatal or nonfatal myocardial infarction
0.730.61–0.88200 vs 268verified
Stroke
Fatal or nonfatal stroke
0.950.76–1.17164 vs 171verified
Hospitalisation for heart failure
Heart failure (hospitalization for heart failure; supportive secondary outcome, labelled 'Heart failure' in Table 2)
0.860.69–1.08146 vs 167verified
CV death or worsening HF
Heart failure events: three-point composite of CV death, urgent visit for heart failure, or hospitalization for heart failure
0.900.79–1.03405 vs 443verified
Kidney composite
Major kidney disease events (first confirmatory secondary): five-point composite of CV death, kidney-related death, persistent eGFR decline of >=50%, persistent
0.910.80–1.05403 vs 435verified
Expanded MACE (MACE + revasc. + UA)
MACE five-point composite: death from CV causes, nonfatal MI, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina
0.840.76–0.93670 vs 777verified
Major adverse limb events
Major adverse limb events, two-point composite: hospitalization for acute limb ischemia or hospitalization for chronic limb ischemia (confirmatory secondary)
0.710.52–0.9671 vs 99verified
Coronary revascularisation
Coronary revascularization
0.750.62–0.90200 vs 263verified
Hospitalisation for unstable angina
Hospitalization for unstable angina pectoris
0.920.67–1.2674 vs 80verified
Verbatim quotes (12)
  • 3-point MACE · Results, Primary and Confirmatory Secondary Outcomes; Table
    579 of the 4825 participants (12.0%...) in the oral semaglutide group, as compared with 668 of the 4825 participants (13.8%...) in the placebo group (hazard ratio, 0.86; 95% CI, 0.77 to 0.96
  • Cardiovascular death · Results, paragraph 2; Table 2; Figure 1B
    301 participants (6.2%) in the oral semaglutide group and 320 participants (6.6%) in the placebo group died from cardiovascular causes (hazard ratio, 0.93; 95% CI, 0.80 to 1.09)
  • All-cause death · Table 2; Results, Supportive Secondary Outcomes
    Death from any cause 528 (10.9) 2.8 577 (12.0) 3.0 0.91 (0.80–1.02)
  • Myocardial infarction · Table 2; Results, Supportive Secondary Outcomes
    Fatal or nonfatal myocardial infarction 200 (4.1) 1.1 268 (5.6) 1.4 0.73 (0.61–0.88)
  • Stroke · Table 2; Results, Supportive Secondary Outcomes
    Fatal or nonfatal stroke 164 (3.4) 0.9 171 (3.5) 0.9 0.95 (0.76–1.17)
  • Hospitalisation for heart failure · Table 2
    Heart failure 146 (3.0) 0.8 167 (3.5) 0.9 0.86 (0.69–1.08)
  • CV death or worsening HF · Table 2; Results, Supportive Secondary Outcomes
    Heart failure events, three-point composite 405 (8.4) 2.1 443 (9.2) 2.4 0.90 (0.79–1.03)
  • Kidney composite · Results, paragraph 4; Table 2; Figure 1E
    an event occurred in 403 participants (8.4%...) in the oral semaglutide group, as compared with 435 participants (9.0%...) in the placebo group (hazard ratio, 0.91; 95% CI, 0.80 to 1.05; P = 0.19)
  • Expanded MACE (MACE + revasc. + UA) · Table 2, supportive secondary outcomes
    Major adverse cardiovascular events, five-point com- posite‖ 670 (13.9) 3.6 777 (16.1) 4.3 0.84 (0.76–0.93)
  • Major adverse limb events · Table 2, confirmatory secondary outcomes
    Major adverse limb events, two-point composite¶ 71 (1.5) 0.4 99 (2.1) 0.5 0.71 (0.52–0.96)
  • Coronary revascularisation · Table 2, supportive secondary outcomes
    Coronary revascularization 200 (4.1) 1.1 263 (5.5) 1.4 0.75 (0.62–0.90)
  • Hospitalisation for unstable angina · Table 2, supportive secondary outcomes
    Hospitalization for unstable angina pectoris 74 (1.5) 0.4 80 (1.7) 0.4 0.92 (0.67–1.26)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: SOUL. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/soul/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.